Q1 Earnings Forecast for ImmunityBio Issued By HC Wainwright

ImmunityBio, Inc. (NASDAQ:IBRX) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of ImmunityBio in a research report issued on Thursday, March 6th. HC Wainwright analyst A. Maldonado forecasts that the company will earn ($0.12) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for ImmunityBio’s Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.45) EPS, FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at $0.03 EPS and FY2029 earnings at $0.29 EPS.

Several other equities research analysts have also recently weighed in on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of ImmunityBio in a research report on Friday, February 28th. BTIG Research initiated coverage on shares of ImmunityBio in a report on Friday, January 10th. They set a “buy” rating and a $6.00 price target for the company. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.19.

ImmunityBio Stock Performance

IBRX opened at $3.00 on Monday. ImmunityBio has a 52-week low of $2.28 and a 52-week high of $10.53. The firm has a market cap of $2.09 billion, a P/E ratio of -3.26 and a beta of 0.82. The business’s fifty day moving average is $3.05 and its 200-day moving average is $3.70.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.11. The company had revenue of $7.55 million for the quarter, compared to analyst estimates of $8.74 million.

Institutional Trading of ImmunityBio

Several hedge funds and other institutional investors have recently made changes to their positions in IBRX. Stephens Inc. AR bought a new stake in ImmunityBio during the 4th quarter worth approximately $26,000. Cibc World Markets Corp acquired a new position in shares of ImmunityBio during the fourth quarter worth $35,000. Maia Wealth LLC bought a new stake in shares of ImmunityBio in the fourth quarter worth $37,000. GF Fund Management CO. LTD. acquired a new stake in ImmunityBio in the fourth quarter valued at $37,000. Finally, Schechter Investment Advisors LLC bought a new position in ImmunityBio during the 4th quarter worth $38,000. 8.58% of the stock is currently owned by institutional investors.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.